%0 Journal Article %A Keno-Kyrill Bressem %A Janis L. Vahldiek %A Lisa Adams %A Stefan Niehues %A Hildrun Haibel %A Valeria Rios Rodriguez %A Murat Torgutalp %A Mikhail Protopopov %A Fabian Proft %A Judith Rademacher %A Joachim Sieper %A Martin Rudwaleit %A Bernd Hamm %A Marcus Makowski %A Kay Geert A. Hermann %A Denis Poddubnyy %T Development and validation of an artificial intelligence approach for the detection of radiographic sacroiliitis %D 2020 %R 10.1101/2020.05.19.20105304 %J medRxiv %P 2020.05.19.20105304 %X Objectives To develop and validate an artificial neural network for the detection of definite radiographic sacroiliitis as a manifestation of axial spondyloarthritis.Methods Conventional radiographs of sacroiliac joints from two independent cohorts of patients with axial spondyloarthritis (axSpA) were used. The first cohort consisted of 1669 radiographs and was used for training and validation of a neural network. The second cohort consisted of 525 radiographs, of which 100 radiographs were randomly selected for the test dataset. In both cohorts all radiographs underwent central reading; the final decision on the presence or absence of definite radiographic sacroiliitis was used as a reference. For performance evaluation of the neural network, areas under the receiver operating characteristic curves (AUROC) were calculated. Sensitivity and specificity for the prediction cut-offs were calculated. Cohen’s Kappa and the absolute agreement were used to assess the agreement between the neural network and the human readers.Results The neural network achieved an excellent performance in recognition of definite radiographic sacroiliitis with AUROC of 0.97 and 0.96 for the validation and test datasets, respectively. Sensitivity and specificity for the cut-off weighting both measurements equally were 0.90 and 0.93 for the validation and 0.87 and 0.97 for the test set. The Cohen’s kappa between the neural network and the reference judgements were 0.80 for both validation and test sets, and the absolute agreement on the classification yielded 91% and 90%, respectively.Conclusions Artificial neural networks enable the accurate detection of definite radiographic sacroiliitis relevant for the diagnosis and classification of axSpA.Competing Interest StatementK.-K.B., L.A., J.R., M.T. and M.M. have nothing to disclose. J.L.V reports non-financial support from Bayer, non-financial support from Guerbet, non-financial support from Medtronic, personal fees and non-financial support from Merit Medical, outside the submitted work S.M.N. reports grants from Deutsche Forschungsgemeinschaft, personal fees from Bracco Imaging, personal fees from Canon Medical Systems, personal fees from Guerbet, personal fees from Teleflex Medical GmbH, personal fees from Bayer Vital GmbH, outside the submitted work. H.H. reports personal fees from Pfizer, personal fees from Janssen, personal fees from Novartis, personal fees from Roche, personal fees from MSD, outside the submitted work. V.R.R. reports personal fees from Abbvie, personal fees from Novartis, outside the submitted work. M.P. reports personal fees from Novartis, personal fees from AbbVie, outside the submitted work. F.P. reports personal fees from AbbVie, personal fees from AMGEN, personal fees from BMS, personal fees from Celgene, from MSD, grants and personal fees from Novartis, personal fees from Pfizer, from Roche, personal fees from UCB, outside the submitted work. J.S. reports grants from AbbVie, during the conduct of the study; personal fees from AbbVie, personal fees from Novartis, personal fees from Pfizer, personal fees from Roche, personal fees from UCB, personal fees from Boehringer Ingelheim, personal fees from Janssen, personal fees from Merk, outside the submitted work. M.R. received honoraria and/or consulting fees from AbbVie, BMS, Celgene, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB Pharma. B.H. reports grants from Abbot, grants from Actelion Pharmaceuticals, grants from Bayer Schering Pharma, grants from Bayer Vital, grants from BRACCO Group, grants from Bristol-Myers Squibb, grants from Charite Research Organisation GmbH, grants from Deutsche Krebshilfe, grants from Essex Pharma, grants from Guerbet, grants from INC Research, grants from lnSightec Ud, grants from IPSEN Pharma, grants from Kendlel MorphoSys AG, grants from Lilly GmbH, grants from MeVis Medical Solutions AG, grants from Nexus Oncology, grants from Novartis, grants from Parexel Clinical Research Organisation Service, grants from Pfizer GmbH, grants from Philipps, grants from Sanofis-Aventis, grants from Siemens, grants from Teruma Medical Corporation, grants from Toshiba, grants from Zukunftsfond Berlin, grants from Amgen, grants from AO Foundation, grants from BARD, grants from BBraun, grants from Boehring Ingelheimer, grants from Brainsgate, grants from CELLACT Pharma, grants from CeloNova Bio-Sciences, grants from GlaxoSmithKline, grants from Jansen, grants from Roehe, grants from Sehumaeher GmbH, grants from Medronic, grants from Pluristem, grants from Quintiles, grants from Roehe, grants from Astellas, grants from Chiltern, grants from Respicardia, grants from TEVA, grants from Abbvie, grants from AstraZenaca, grants from Galmed Research and Development Ltd, outside the submitted work. K.G.H. reports personal fees from AbbVie, personal fees from Pfizer, personal fees from MSD, personal fees from Roche, outside the submitted work. D.P. reports grants and personal fees from AbbVie, during the conduct of the study; grants and personal fees from AbbVie, personal fees from BMS, personal fees from Celgene, grants and personal fees from Lilly, grants and personal fees from MSD, grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Roche, personal fees from UCB, outside the submitted work.Funding StatementGESPIC was initially supported by the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung–BMBF). As consequence of the funding reduction by BMBF according to schedule in 2005 and stopped in 2007, complementary financial support has been obtained also from Abbott, Amgen, Centocor, Schering–Plough, and Wyeth. Starting from 2010, the core GESPIC cohort was supported by AbbVie. The PROOF study is funded by AbbVie. We would like to thank AbbVie for allowing the use of the PROOF dataset for the aim of the current study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request. %U https://www.medrxiv.org/content/medrxiv/early/2020/05/22/2020.05.19.20105304.full.pdf